Navigation Links
Data To Be Presented at ASCO Supports Potential of Peregrine's Cotara(R) for the Treatment of Brain Cancer
Date:5/31/2008

tara trial to the next stage," said Dr. Kevin Judy, associate professor neurosurgery at the University of Pennsylvania School of Medicine and a principal investigator of the Cotara dosimetry trial. "Cotara's good safety profile to date is especially encouraging in view of the toxicity of the treatment options currently available to GBM patients. We look forward to further assessing its safety and anti-tumor activity at the higher doses we plan to use in the next stages of the trial."

The open label dose confirmation and dosimetry study at U.S. brain cancer centers is enrolling GBM patients with recurrent disease. Patients in this trial receive an initial imaging dose of Cotara before receiving the therapeutic dose.

"These positive data validate a key principle underlying the Cotara program, confirming its ability to specifically concentrate in and deliver a high radiation dose to brain tumors," said Steven W. King, president and CEO of Peregrine. "These results also further confirm the key targeting attribute of Cotara, showing it results in minimal radiation exposure to other organs, including the thyroid. We also are encouraged that patients in this initial, low-dose cohort have already lived longer than the expected median survival time for GBM patients at first relapse, and we look forward to reporting further data on Cotara in the coming months."

The dosimetry study's main objectives are to confirm the maximum tolerated dose of Cotara, to determine radiation dosimetry and to assess overall patient survival, progression-free survival and the proportion of patients alive at six months following Cotara administration. In addition to the University of Pennsylvania Medical Center, the Medical University of South Carolina in Charleston and the Barrow Neurological Institute in Phoenix, Arizona are participating in the trial. A fourth study site was recently initiated at Case Western Reserve University in Cleveland, Ohio. Peregrine is also conducti
'/>"/>

SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
2. Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
3. Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
4. Safety and Efficacy Results Presented From Largest Prospective Controlled Clinical Study of Ulcerative Colitis
5. Analysis of Ulcerative Colitis (UC) Time to Symptom Resolution Data from Pivotal Study of LIALDA(TM) (mesalamine) Presented at DDW
6. New Data Highlighting Possible Impact of ESA Reimbursement Policies on Patient Care, Nations Blood Supply, to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
7. Eisais Commitment to Oncology Demonstrated by Clinical Data to be Presented at ASCO Annual Meeting
8. New Roche Data to be Presented at ASCO Offers Further Hope for Cancer Patients
9. XTENT Announces Positive Six-Month CUSTOM III Trial Data Presented at EuroPCR Meeting
10. Results of the Phase III Pivotal Study of VYVANSE(TM) (Lisdexamfetamine Dimesylate) for the Treatment of ADHD in Adults Presented at National Scientific Meeting of Psychiatrists
11. Overview of Asenapine Data from Olympia Trial Program Presented at American Psychiatric Association Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... Inc. (OTC: SIMH, SIMHD) ("Sanomedics" or the "Company"), an ... acquiring cutting-edge technology, products and services announced today that ... booth # 709 at the National Association of ... March 11-13, 2015 at Caesars Palace in ... 36 th annual NAPNAP Conference will bring over ...
(Date:3/5/2015)... , March 5, 2015  AMRI (NASDAQ: ... , fills the newly created position of VP of ... Conway , Senior Vice President of Global Sales and ... will lead the international sales team in an effort ... in targeted market segments. Mr. Pettersson will drive strategy ...
(Date:3/5/2015)... 2015 Research and Markets ( http://www.researchandmarkets.com/research/4q7gwz/india_pharma ... Pharma Outlook 2015: Accelerating growth to the next level ... report to their offering. Domestic sales ... 2013 caused by the market,s reaction to the new ... continue to be healthy, as the momentum continues and ...
Breaking Medicine Technology:Sanomedics to Showcase the Caregiver at National Association of Pediatric Nurse Practitioners Conference 2Sanomedics to Showcase the Caregiver at National Association of Pediatric Nurse Practitioners Conference 3AMRI Hires VP of International Sales 2India Pharma Outlook 2015: Accelerating growth to the next level - Moving up the value chain beyond Generics 2India Pharma Outlook 2015: Accelerating growth to the next level - Moving up the value chain beyond Generics 3
... insights into global patent and trademark trends with the ... brand protection trends throughout 2011. The two reports, ... Their States of Innovation and ... track patent and trademark activity in key technology ...
... March 10, 2012 Omnicell, Inc ., (NASDAQ: ... medication and supply management solutions and analytics software for ... the Dubai International Pharmaceuticals and Technologies Conference and Exhibition ... Exhibition Centre. DUPHAT is one of the most recognized ...
Cached Medicine Technology:Patent and Trademark Trends 2011: Thomson Reuters Evaluates the State of Global IP 2Omnicell to Exhibit at Dubai International Pharmaceuticals and Technologies Conference and Exhibition 2
(Date:3/5/2015)... Central Nebraska Imaging (CNI) is pleased ... brand’s new logo and optimized website. , ... approach to expert diagnostic imaging, centered on patient care. ... to be a resource for Nebraska patients and a ... communication and referral functionality, video content and resources to ...
(Date:3/5/2015)... 05, 2015 HomeCEUConnection.com is ... with extra savings on their nutrition CEUs. ... health and nutrition, HomeCEUConnection.com is offering 10% ... promo code, NUTRITION2015 . , High ... , HomeCEUConnection.com provides high-quality continuing education courses ...
(Date:3/5/2015)... CA (PRWEB) March 05, 2015 On ... titled “Butt Augmentation, Labiaplasty on the Rise, Plastic Surgeons ... by the American Society for Aesthetic Plastic Surgery ... . Both groups reported a year-over-year doubling of surgical ... the physicians quoted in the article, this increase can ...
(Date:3/5/2015)... (PRWEB) March 05, 2015 In honor ... to shatter myths about drug and alcohol abuse in ... released a Fact Sheet with information on some of ... in 2010 by the National Institute on Drug Abuse, ... alcohol aims to counteract the illusions that teens and ...
(Date:3/5/2015)... At the 7th Annual Mississippi Addiction ... treatment met today in Jackson, Mississippi to listen to ... the numerous respected speakers will be William S. ... that pain medications have had in today’s opiate overdose ... "It is hard to believe that much of the ...
Breaking Medicine News(10 mins):Health News:Central Nebraska Imaging Center Gets Rebranding 2Health News:HomeCEUConnection.com Offers Nutrition CEUs this March to Celebrate Nutrition Month 2Health News:The Kim Kardashian and Jennifer Lopez Effect: Butt Augmentations Double from 2013 to 2014 2Health News:A Forever Recovery Issues New Tips for Sobriety for National Drug Facts Week 2Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 2Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 3
... Rights to Bystolic(TM) (Nebivolol) for $370 Million in Cash ... To Consider a Sale of Dey Specialty Business, PITTSBURGH, Feb. ... results for the three and nine months ended,December 31, 2007, provided ... announced a number of strategic and operational,initiatives., Financial Highlights, ...
... New research from a scientist at the University of ... to a better flu vaccine. , While the research ... findings from Mark Sangster, a professor of microbiology, track ... infection and reveal new information about where it is ...
... University School of Medicine and Harvard Medical School have ... of high blood pressure, reduces cocaine cravings in a ... issue of the leading medical journal Nature Neuroscience. , ... glutamate, independently contribute to the development of cocaine addiction. ...
... ROCKVILLE, Md., Feb. 27 Novavax, Inc.,(Nasdaq: NVAX ... Singhvi, President and Chief Executive Officer, will be presenting ... 12:30 p.m. on March 4, 2008 at The W ... of the company,s strategy, research and,development progress. A link ...
... 27 Dr. Shawn Hook of Arbor Ridge,Clinic in ... Summit,VetPharm,s "The Great Vectra 3D(TM)" $125,000 Giveaway. Dr. Hook ... receive $25,000 in,medical equipment for his veterinary clinic. There ... February and March, and a final grand prize,winner who ...
... numbers of circulating,cancer cells in a blood sample; ... RARITAN, N.J., Feb. 27 Veridex, LLC ... (FDA) has granted an expanded,clearance for the CellSearch(TM) ... the,monitoring of metastatic prostate cancer (MPC) patients. The ...
Cached Medicine News:Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 2Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 3Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 4Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 5Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 6Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 7Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 8Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 9Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 10Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 11Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 12Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 13Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 14Health News:Mylan Reports Adjusted Diluted Cash EPS of $0.11 for the Quarter 15Health News:UT Knoxville research may lead to better flu vaccine 2Health News:Summit VetPharm Announces First Winner in its 'Great Vectra 3D(TM)' $125,000 Giveaway 2Health News:FDA Clears Cellsearch(TM) Circulating Tumor Cell Test for Monitoring Metastatic Prostate Cancer Patients 2Health News:FDA Clears Cellsearch(TM) Circulating Tumor Cell Test for Monitoring Metastatic Prostate Cancer Patients 3Health News:FDA Clears Cellsearch(TM) Circulating Tumor Cell Test for Monitoring Metastatic Prostate Cancer Patients 4
Curved shafts with delicate 1 x 2 teeth. Serrated handle. Polished finish....
Inner jaw space 2.0 mm - 45 degree tip angulation. 20 gauge (.89 mm) diameter shaft and stationary distal jaw. Lightweight squeeze handle with dull finish. Jaws 1.5 mm serrated....
Straight shafts with 1 x 2 teeth. Flat handle with polished finish....
Straight shafts with heavy 1 x 2 teeth. Non-magnetic with serrated handle and polished finish....
Medicine Products: